Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance ...

Data quality issues and increased rates of claim denials provide opportunities for artificial intelligence to make ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...